← All trials
NCT04370223
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 4, 2020
- Primary completion
- Oct 25, 2020
- Completion date
- Dec 25, 2020
- First posted
- Apr 30, 2020
- Last posted
- May 5, 2020
- Enrollment
- 208
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Institut d'Investigació Biomèdica de Girona Dr. Josep TruetaLead sponsor
- Institut d'Investigació Biomèdica de Girona Dr. Josep TruetaReponsible party - principal investigator
- Sociedad Española de OzonoterapiaCollaborator
- Clínica Virgen del Rosario, AlgecirasCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.